Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Long-term survival in a patient with metastatic squamous cell lung carcinoma: A case report.

Barletta E, Federico P, Tinessa V, Germano D, Cannella L, Pironti T, Daniele B.

Mol Clin Oncol. 2017 Nov;7(5):928-930. doi: 10.3892/mco.2017.1408. Epub 2017 Sep 1.

2.

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.

Ascierto PA, Daniele B, Hammers H, Hirsh V, Kim J, Licitra L, Nanda R, Pignata S.

J Transl Med. 2017 Oct 11;15(1):205. doi: 10.1186/s12967-017-1309-2.

3.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.

Medicine (Baltimore). 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817.

4.

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.

Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J.

World J Gastroenterol. 2017 Apr 7;23(13):2448-2452. doi: 10.3748/wjg.v23.i13.2448.

5.

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma.

Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz B, Santoro A, Rimassa L.

Oncotarget. 2017 Feb 28;8(9):14408-14415. doi: 10.18632/oncotarget.14797.

6.

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.

Rimassa L, Abbadessa G, Personeni N, Porta C, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, De Toni EN, Weiss A, Miles S, Gasbarrini A, Lencioni M, Lamar ME, Wang Y, Shuster D, Schwartz BE, Santoro A.

Oncotarget. 2016 Nov 8;7(45):72622-72633. doi: 10.18632/oncotarget.11621.

7.

Epithelioid hemangioma of brachial artery: report of a case and review of the literature.

Moira R, Giuseppe F, Riccardo V, Nicola R, Daniele B, Pierfrancesco C, Antonio DC, Antonello A, Bruno A, Giovanni C, Guglielmo F.

Open Med (Wars). 2015 Dec 17;10(1):502-507. doi: 10.1515/med-2015-0085. eCollection 2015. Review.

8.

Gender differences in the efficacy of cardiovascular rehabilitation in patients after cardiac surgery procedures.

Feola M, Garnero S, Daniele B, Mento C, Dell'Aira F, Chizzolini G, Testa M.

J Geriatr Cardiol. 2015 Sep;12(5):575-9. doi: 10.11909/j.issn.1671-5411.2015.05.015. No abstract available.

9.

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014.

Ascierto PA, Addeo R, Cartenì G, Daniele B, De Laurentis M, Ianniello GP, Morabito A, Palmieri G, Pepe S, Perrone F, Pignata S, Montesarchio V.

J Transl Med. 2014 Oct 21;12:291. doi: 10.1186/s12967-014-0291-1. Review.

10.

TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis.

Germano D, Daniele B.

Hepatobiliary Surg Nutr. 2014 Aug;3(4):166-7. doi: 10.3978/j.issn.2304-3881.2014.06.04.

11.

Systemic therapy of hepatocellular carcinoma: current status and future perspectives.

Germano D, Daniele B.

World J Gastroenterol. 2014 Mar 28;20(12):3087-99. doi: 10.3748/wjg.v20.i12.3087. Review.

12.

Dose-dense FEC followed by dose-dense ixabepilone as neoadjuvant treatment for breast cancer patients: a feasibility study.

Clavarezza M, Bordonaro R, Daniele B, Ferrandina G, Barni S, Turazza M, Coati F, De Matteis A, De Placido S, Cognetti F, Olmeo NA, Carrozza F, Bruzzi P, Del Mastro L; Gruppo Italiano Mammella.

Oncologist. 2013;18(8):924-5. doi: 10.1634/theoncologist.2013-0222. Epub 2013 Aug 12. Erratum in: Oncologist. 2013;18(10):1149.

13.

Right-sided rhabdoid colorectal tumors might be related to the serrated pathway.

Pancione M, Remo A, Sabatino L, Zanella C, Votino C, Fucci A, Di Blasi A, Lepore G, Daniele B, Fenizia F, Molinari E, Normanno N, Manfrin E, Vendraminelli R, Colantuoni V.

Diagn Pathol. 2013 Feb 20;8:31. doi: 10.1186/1746-1596-8-31.

14.

Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients.

Signoriello S, Annunziata A, Lama N, Signoriello G, Chiodini P, De Sio I, Daniele B, Di Costanzo GG, Calise F, Olivieri G, Castaldo V, Lanzetta R, Piai G, Marone G, Visconti M, Fusco M, Di Maio M, Perrone F, Gallo C, Gaeta GB.

ScientificWorldJournal. 2012;2012:564706. doi: 10.1100/2012/564706. Epub 2012 May 3.

15.

The non-anticoagulant heparin-like K5 polysaccharide derivative K5-N,OSepi attenuates myocardial ischaemia/reperfusion injury.

Collino M, Pini A, Mastroianni R, Benetti E, Lanzi C, Bani D, Manoni M, Fantozzi R, Masini E.

J Cell Mol Med. 2012 Sep;16(9):2196-207. doi: 10.1111/j.1582-4934.2012.01530.x. Erratum in: J Cell Mol Med. 2013 Dec;17(12):1652. Massimo, Collino [corrected to Collino, Massimo]; Alessandro, Pini [corrected to Pini, Alessandro]; Rosanna, Mastroianni [corrected to Mastroianni, Rosanna]; Elisa, Benetti [corrected to Benetti, Elisa]; Cecilia, Lanzi [corrected to Lanzi, Cecilia]; Daniele, Bani [corrected to Bani, Daniele]; Marco, Manoni [corrected to Manoni, Marco]; Roberto, Fantozzi [corrected to Fantozzi, Roberto]; Emanuela, Masini [corrected to Masini, Emanuela]; Jacopo, Chini [removed].

16.

Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.

Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F.

Cancers (Basel). 2012 Jun 5;4(2):549-65. doi: 10.3390/cancers4020549.

17.

Is human hepatocellular carcinoma a hormone-responsive tumor?

Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Morabito A, Piccirillo MC, Perrone F.

World J Gastroenterol. 2008 Mar 21;14(11):1682-9. Review.

18.

Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma.

Gallo C, De Maio E, Di Maio M, Signoriello G, Daniele B, Pignata S, Annunziata A, Perrone F; CLIP (Cancer of the Liver Italian Programme) Investigators.

BMC Cancer. 2006 Jul 24;6:196.

19.

Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients.

Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife C, Raut C, Wolff R, Choi H, Loyer E, Vallone P, Fiore F, Scordino F, De Rosa V, Orlando R, Pignata S, Daniele B, Izzo F.

Ann Surg. 2004 Apr;239(4):450-8.

20.

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial.

Daniele B, Perrone F, Gallo C, Pignata S, De Martino S, De Vivo R, Barletta E, Tambaro R, Abbiati R, D'Agostino L.

Gut. 2001 Jan;48(1):28-33.

Supplemental Content

Loading ...
Support Center